Mechanism of Action

Modulates expression of ~4,000 human genes (31.2% of genome). Stimulates collagen/elastin/GAG synthesis, angiogenesis, antioxidant enzymes (SOD), and BDNF. Declines from ~200 ng/mL at age 20 to ~80 ng/mL by age 60.

Clinical Use

Topical: wound healing, skin rejuvenation (cosmetic). Injectable: FDA-prohibited since 2023. Hair restoration with microneedling.

Contraindications

Active infections at application site. Known copper sensitivity. Pregnancy.

Evidence Summary

Strong topical/cosmetic evidence. Genomic analysis showing broad gene expression influence. Injectable use FDA-prohibited as of 2023.

Key Studies
  • 1.Pickart L et al., Biomed Res Int 2015 — accelerates wound healing. Stimulates collagen, dermatan sulfate, decorin. Resets DNA to healthier gene expression state. Review
  • 2.Pickart L, Margolina A, Int J Mol Sci 2018 — GHK-Cu influences 31.2% of human genes. Suppresses metastasis-associated genes. Genomic analysis
Evidence Gaps

Most clinical data is topical/cosmetic. Limited systemic human studies. Injectable compounding FDA-prohibited.

Emerging Research

Hair restoration (microneedling showing 26.5% regrowth). COVID-19 lung fibrosis research. COPD therapeutic development.

iRemedy Sourcing Status
RESEARCH / INVESTIGATIONAL
Topical cosmetic API available. Injectable compounding FDA-prohibited as of 2023.

iRemedy is a 50-state licensed, NABP-accredited wholesale distributor. Peptides supplied with full CoA, DSCSA serialization, and UPS Healthcare cold chain logistics. Wholesale to licensed healthcare facilities and compounding pharmacies only.

← Back to Peptide Library ← Previous: FOXO4-DRI Next: GHRP-2 →
Request Peptide Catalog →